Page 132 - 《中国药房》2025年8期

[17] LIU J，LIN S，HUYNH A，et al. Effects of H2-receptor an‐ modeling approach[J]. Front Pharmacol，2024，15：
tagonists on the exposure of dacomitinib[J]. Pharmaceu‐ 1363259.
tics，2024，16（1）：118. [27] DARRÉ H，MASSON P，NATIVEL A，et al. Comparing
[18] DELIWALA S S，HAMID K，GOYAL H，et al. Proton the efficacy of two generations of EGFR-TKIs：an inte‐
pump inhibitors versus histamine-2-receptor antagonists grated drug-disease mechanistic model approach in EGFR-
for stress ulcer prophylaxis in critically ill patients：a meta- mutated lung adenocarcinoma[J]. Biomedicines，2024，12
analysis and trial sequential analysis[J]. J Clin Gastroen‐ （3）：704.
terol，2022，56（3）：204-217. [28] JAKUBIAK P，WAGNER B，GRIMM H P，et al. Develop‐
[19] 张露丹，左旭锐，刘凡琪，等. 应用定量药理学模型开展 ment of a unified dissolution and precipitation model and
中西药相互作用的研究进展[J]. 中草药，2024，55（6）： its use for the prediction of oral drug absorption[J]. Mol
1799-1805. Pharm，2016，13（2）：586-598.
[20] EL BIALI M，WÖLFL-DUCHEK M，JACKWERTH M， [29] NARITOMI Y，SANOH S，OHTA S. Utility of chimeric
et al. St. John’s wort extract with a high hyperforin con‐ mice with humanized liver for predicting human pharma‐
tent does not induce P-glycoprotein activity at the human cokinetics in drug discovery：comparison with in vitro-in
blood-brain barrier[J]. Clin Transl Sci，2024，17（5）： vivo extrapolation and allometric scaling[J]. Biol Pharm
e13804. Bull，2019，42（3）：327-336.
[21] MASHAYEKHI-SARDOO H，MASHAYEKHI-SARDOO [30] BI Y W，DENG J X，MURRY D J，et al. A whole-body
A，ROUFOGALIS B D，et al. Impact of curcumin on physiologically based pharmacokinetic model of gefitinib
microsomal enzyme activities：drug interaction and in mice and scale-up to humans[J]. AAPS J，2016，18（1）：
chemopreventive studies[J]. Curr Med Chem，2021，28 228-238.
（34）：7122-7140. [31] VAN DE STADT E A，YAQUB M，LAMMERTSMA A A，
[22] PILLA REDDY V，JO H，NEUHOFF S. Food constituent- et al. Identifying advanced stage NSCLC patients who
and herb-drug interactions in oncology：influence of quan‐ benefit from afatinib therapy using F-afatinib PET/CT
18
titative modelling on drug labelling[J]. Br J Clin Pharma‐ imaging[J]. Lung Cancer，2021，155：156-162.
col，2021，87（10）：3988-4000. [32] BAHCE I，YAQUB M，SMIT E F，et al. Personalizing
[23] CHEN Y X，ZHOU D S，TANG W F，et al. Physiologi‐ NSCLC therapy by characterizing tumors using TKI-PET
cally based pharmacokinetic modeling to evaluate the sys‐ and immuno-PET[J]. Lung Cancer，2017，107：1-13.
temic exposure of gefitinib in CYP2D6 ultrarapid metabo‐ [33] YAQUB M，BAHCE I，VOORHOEVE C，et al. Quantita‐
lizers and extensive metabolizers[J]. J Clin Pharmacol， tive and simplified analysis of C-erlotinib studies[J]. J
11
2018，58（4）：485-493. Nucl Med，2016，57（6）：861-866.
[24] CHEONG E J Y，NG D Z W，CHIN S Y，et al. Applica‐ [34] BARTELINK I H，VAN DE STADT E A，LEEUWERIK
tion of a physiologically based pharmacokinetic model of A F，et al. Physiologically based pharmacokinetic（PBPK）
rivaroxaban to prospective simulations of drug-drug- modeling to predict PET image quality of three genera‐
disease interactions with protein kinase inhibitors in tions EGFR TKI in advanced-stage NSCLC patients[J].
cancer-associated venous thromboembolism[J]. Br J Clin Pharmaceuticals（Basel），2022，15（7）：796.
Pharmacol，2022，88（5）：2267-2283. [35] GRUBER A，CZEJKA M，BUCHNER P，et al. Monito-
[25] SHARMA J，LV H，GALLO J M. Intratumoral modeling ring of erlotinib in pancreatic cancer patients during long-
of gefitinib pharmacokinetics and pharmacodynamics in time administration and comparison to a physiologically
an orthotopic mouse model of glioblastoma[J]. Cancer based pharmacokinetic model[J]. Cancer Chemother Phar‐
Res，2013，73（16）：5242-5252. macol，2018，81（4）：763-771.
[26] LIANG F，ZHANG Y M，XUE Q，et al. Exploring inter- （收稿日期：2024-10-28 修回日期：2025-03-28）
ethnic and inter-patient variability and optimal dosing of （编辑：李 劲）
osimertinib：a physiologically based pharmacokinetic

· 1018 · China Pharmacy 2025 Vol. 36 No. 8 中国药房 2025年第36卷第8期